NovaBridge Biosciences (NBP) Non-Current Deferred Tax Liability (2018 - 2022)

NovaBridge Biosciences (NBP) has reported Non-Current Deferred Tax Liability for 3 consecutive years, with $2.5 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Non-Current Deferred Tax Liability fell 10.69% year-over-year to $2.5 million; the TTM figure through Dec 2022 stood at $2.5 million (down 10.69% YoY), while the FY2022 annual figure was $2.6 million, down 7.93% from the prior year.
• Non-Current Deferred Tax Liability eased to $2.5 million in Q4 2022 per NBP's latest filing, from $2.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $5.4 million in Q4 2018 and bottomed at $2.5 million in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $3.6 million across 3 years, with a median of $2.8 million in 2021.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 10.69% in 2022 and fell as far as 10.69% in 2022.
• NovaBridge Biosciences' Non-Current Deferred Tax Liability stood at $5.4 million in 2018, then sank by 47.83% to $2.8 million in 2021, then dropped by 10.69% to $2.5 million in 2022.
• Business Quant data shows NBP's Non-Current Deferred Tax Liability at $2.5 million in Q4 2022, $2.8 million in Q4 2021, and $5.4 million in Q4 2018.